Crinetics' PALSONIFY shows lasting acromegaly control in new ENDO 2026 data

Crinetics Pharmaceuticals has presented new long-term data for its acromegaly treatment, PALSONIFY, at ENDO 2026. The findings show sustained effectiveness and tolerability in patients over extended periods. In the PATHFNDR-1 study, IGF-1 levels remained stable at 0.81 times the upper limit of normal after 96 weeks of PALSONIFY treatment. Patients switched from monthly injectable somatostatin receptor ligands also showed stable acromegaly symptoms and pituitary tumour volumes at 48 weeks. After two years, the drug was confirmed as both effective and well-tolerated.

PATHFNDR-2 results demonstrated a reduction in IGF-1 levels from 1.64 times to 0.96 times the upper limit of normal over 72 weeks. Additionally, seven patients experienced a greater than 20% reduction in pituitary tumour volume by 24 weeks.

In the ACROBAT Advance study, PALSONIFY combined with oral cabergoline improved IGF-1 levels and was well-tolerated. The pooled open-label extension population of 167 patients reported no new safety signals. The most frequent adverse events were diarrhoea, joint pain, headaches, and urinary tract infections. Four patients discontinued treatment due to side effects. The data confirms PALSONIFY’s long-term stability in managing acromegaly. It maintains IGF-1 control, reduces tumour size in some cases, and demonstrates a consistent safety profile. These results support its use as a reliable treatment option for patients.